Hemex Health launches first dx for Gazelle platform

Create PDF

July 2020—Hemex Health (Portland, Ore.) launched the company’s Gazelle diagnostic platform, which integrates artificial intelligence with automated, miniaturized electrophoresis and internal and cloud-based data storage. The battery-operated platform uses an Android cell-phone charger and does not require a cold chain.

The Gazelle features an Hb variant test that automatically identifies and quantifies sickle cell and other Hb ­variants from a small blood sample in eight minutes. The test is CE marked and has regulatory approval in India and Ghana, with other country registrations pending.

The platform also includes a CE-marked test for malaria that delivers results in about one minute and is highly sensitive for Plasmodium vivax infections.